1. To present results of a phase II study of pembrolizumab and ipilimumab following initial anti-PD1/L1 antibody

2. To review associated toxicities of immune checkpoint inhibitors and our current understanding of toxicity mechanisms.

3. To learn the role of tissue-resident memory T cells in immunotherapy response and their potential role as biomarker for immune-related adverse events.ng initial anti-PD1/L1 antib

Session date: 
03/23/2020 - 12:00pm to 1:00pm CDT
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Daniel J. Olson, M.D.